Health Care

Boston Scientific announced plans on Wednesday to axe up to 1,500 positions and expects to report softer-than-expected revenue for the full year.

Bristol-Myers Squibb reported better-than-expected quarterly earnings, fueled by strong sales of cancer and diabetes drugs.

Travelers reported a 3Q profit beating expectations, and a $5 billion buyback program, sending its shares up 3% pre-market.

Nestle reportedly spoke to a small group of potential buyers to sell the diet business, as it looks to divest underperforming units.

German drug distributor Celesio is reportedly in advanced talks about being acquired by U.S. rival McKesson for $5.08 billion.

The No. 1 U.S. drug-store operator benefited from stronger pharmacy sales and increased cost synergies.

AstraZeneca scooped up privately held Amplimmune for about half-a-billion dollars as it looks to strengthen its pipeline of cancer drugs.

No one said that overhauling healthcare, which accounts for 17% of all national spending, was going to happen with a skeleton crew.

The drugstore chain posted its third consecutive quarterly profit helped by sales of higher-margin generic drugs. 

Johnson & Johnson agreed to acquire privately held drug developer Aragon Pharmaceuticals for as much as $1 billion.

After the Obama administration decided to allow the contraceptive to be sold over the counter without restrictions, drug makers are facing questions over how to market the pill to teens—or whether they should at all.

The highest U.S. court ruled Thursday biotech companies can’t patent your genes. But they can stake claim to derivatives made from the building blocks of nearly all living things.

Pfizer has reached a $2.15 billion settlement with the two companies over patent infringement on its acid-reflux drug Protonix.

Ista Pharmaceuticals pleaded guilty to charges it used kickbacks and improper marketing to boost sales of a drug meant to treat eye pain.

The Department of Health and Human Services announced a $1 billion initiative to fund innovations in federal healthcare programs.

Merck posted weaker-than-expected quarterly sales on increased generic competition as well as a sharp revenue miss and lowered its full-year outlook.

The pharmacy retailer reported lower input costs while margins widened amid an influx of new generic drugs.

U.S. federal prosecutors filed a lawsuit against Novartis Pharmaceuticals, accusing the company of paying kickbacks to doctors in an effort to encourage prescriptions for Novartis drugs.

Bristol-Myers Squibb reported lower first-quarter earnings, in line with forecasts, thanks to unexpectedly lower taxes and sharply higher sales.

The company reported higher-than-expected quarterly earnings due to favorable taxes and cost controls, but sales missed expectations.